{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clinical+Stage+IV+Cutaneous+Melanoma+AJCC+v8", "query": { "condition": "Clinical Stage IV Cutaneous Melanoma AJCC v8" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clinical+Stage+IV+Cutaneous+Melanoma+AJCC+v8&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:34:01.777Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05136196", "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Melanoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Melanoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-12-06", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 222, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 173 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05136196" }, { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sonidegib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-02-13", "completion_date": "2027-07-02", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04007744" }, { "nct_id": "NCT03816332", "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Basal Cell Carcinoma", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Unresectable Basal Cell Carcinoma", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-11-08", "completion_date": "2026-09-19", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 7, "location_summary": "Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816332" }, { "nct_id": "NCT03698019", "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Mucosal Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2019-02-15", "completion_date": "2026-10-30", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 817, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 512 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698019" }, { "nct_id": "NCT04752267", "title": "18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Glioma", "Malignant Brain Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Kidney Carcinoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "18F-FMAU", "type": "DRUG" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-02-15", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752267" }, { "nct_id": "NCT05764395", "title": "Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Refractory Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Rigosertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-05-09", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05764395" }, { "nct_id": "NCT04375527", "title": "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC V8", "Clinical Stage IV Cutaneous Melanoma AJCC V8", "Locally Advanced Cutaneous Melanoma", "Metastatic Cutaneous Melanoma", "Pathologic Stage III Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC V8", "Pathologic Stage IIID Cutaneous Melanoma AJCC V8", "Pathologic Stage IV Cutaneous Melanoma AJCC V8", "Unresectable Cutaneous Melanoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-12-03", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375527" }, { "nct_id": "NCT04990726", "title": "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Melanoma, Stage II", "Melanoma Stage IV" ], "interventions": [ { "name": "Assessment", "type": "BEHAVIORAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2019-12-05", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-05-21T22:34:01.777Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990726" } ] }